
Sign up to save your podcasts
Or
Jonathan Violin, CEO of Crescent Biopharma and Venture Partner at Fairmount, speaks with Venrock partner Nimish Shah about how the company is keeping a frenetic and exciting pace to generate a new class of drugs while preparing to launch on the public markets later this year.
4.8
6262 ratings
Jonathan Violin, CEO of Crescent Biopharma and Venture Partner at Fairmount, speaks with Venrock partner Nimish Shah about how the company is keeping a frenetic and exciting pace to generate a new class of drugs while preparing to launch on the public markets later this year.
1,271 Listeners
2,186 Listeners
1,019 Listeners
991 Listeners
1,780 Listeners
2,301 Listeners
3,978 Listeners
123 Listeners
317 Listeners
5,920 Listeners
1,537 Listeners
30 Listeners
146 Listeners
10 Listeners
44 Listeners